Shareprice
13 Jul 2024

Press & news

FluoGuide develops surgical solutions that is expected to reduce suffering for the patient and increases the likelihood of cure as well as reducing costs for the health care system.

New - New exchange: Nasdaq First North

FluoGuide is moving from Spotlight to Nasdaq First North. Shareholders are strongly encouraged to make sure they will be able to freely trade their shares in the future.

Presentation of data where use of FG001 demonstrates improved surgical outcome in metastatic pancreatic cancer compared to standard surgery using only white light

News


September 6, 2019

FluoGuide A/S’s ("FluoGuide", ticker FLUO) compound FG001 lights up the cancer and has in preclinically studies demonstrated potential to vastly improve the radicality of surgery in different types of cancer. Today data was presented at World Molecular Imaging Congress 2019 (WMIC) in Montreal, demonstrating how FG001 for in vivo fluorescent guidance improved surgical resection of metastatic pancreatic cancer in comparison with traditional white light surgery.

Pancreatic cancer remains one of the deadliest cancers, and the one and five-year survival rates have been reported as 15% and 3% (Carrato 2015), respectively. Radical surgical tumor resection is critical for improved outcome and better survival rates. However, due to generally late diagnosis only a small portion of patients are eligible for surgery. Even in the small group of patients that undergo surgery with curative intent, relapse is frequent. In addition, the low survival rate for pancreatic cancer is due to lack of other effective treatments. Optical guided surgery could be a solution to obtain better surgical outcome.

The study presented had two objectives; (1) Evaluation of the use of FG001 in resection of the primary tumor and metastases in an orthotopic human xenograft pancreatic cancer model using different types of equipment; and (2) Investigation of whether fluorescent-guided imaging using FG001 could locate additional metastases when following conventional removal of metastasis under white light surgery using the da Vinci® Surgical Robotic System operated by a human surgeon.

FG001, a uPAR target fluorescent molecule, was in this study injected intravenously before imaging with two different near-infrared camera systems (Fluobeam800® and the da Vinci® Surgical Robotic System equipment). The result showed that FG001 was an excellent probe for intraoperative optical imaging with a mean tumor-to-background ratio (TBR) for the primary tumor of 3.5 (95% Cl: 3.3; 3.7) and a TBR for the metastases of 3.4 (95% cl: 3.1; 4.0). Further, a benefit using intraoperative fluorescent guidance was shown yielded identification of an additional 14% metastases compared to using normal white light surgery. On a subject basis, in 4 of 8 mice (50%) there were identified additional metastases with FG001 optical imaging compared to white light. 

“Translated to humans, this result indicates that half of the patients undergoing traditional white light surgery would have been sent home with a metastasis that could have been detected and removed using FG001.” Says Morten Albrechtsen, CEO of FluoGuide, and further comments: “We are very excited to bring this promising product forward with the potential to help improve the surgical outcome for patients with pancreatic cancer”

PhD student Karina Juhl from Rigshospitalet and University of Copenhagen, presenting the data concluded that: “the uPAR-targeted optical probe enables intraoperative optical cancer imaging, including during robotic surgery, and may be a benefit for intended radical resection of disseminated pancreas cancer by finding more metastasis than with traditional white light surgery.”